Financial Survey: Actinium Pharmaceuticals (NYSE:ATNM) and BriaCell Therapeutics (NASDAQ:BCTX)

BriaCell Therapeutics (NASDAQ:BCTX) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, dividends, valuation and profitability.

Valuation & Earnings

This table compares BriaCell Therapeutics and Actinium Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BriaCell Therapeutics	N/A	N/A	-$4.79 million	($13.34)	-0.31
Actinium Pharmaceuticals	$81,000.00	427.50	-$48.82 million	($1.39)	-0.80

BriaCell Therapeutics has higher earnings, but lower revenue than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

15.4% of BriaCell Therapeutics shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 5.7% of BriaCell Therapeutics shares are owned by insiders. Comparatively, 6.0% of Actinium Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for BriaCell Therapeutics and Actinium Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BriaCell Therapeutics	0	0	1	0	3.00
Actinium Pharmaceuticals	0	1	4	0	2.80

BriaCell Therapeutics presently has a consensus target price of $32.00, suggesting a potential upside of 665.55%. Actinium Pharmaceuticals has a consensus target price of $7.40, suggesting a potential upside of 566.67%. Given BriaCell Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe BriaCell Therapeutics is more favorable than Actinium Pharmaceuticals.

Risk and Volatility

BriaCell Therapeutics has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500.

Profitability

This table compares BriaCell Therapeutics and Actinium Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BriaCell Therapeutics	N/A	N/A	-191.19%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.